Key facts, as of
As of October 22, 2026, Agilent Technologies (A) trades at $173.89, up 19.2% over the past year. Its 52-week range runs from $108.35 to $179.10; the price is 2.9% below that high. It is 3.2% below its all-time high of $179.57, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +294.8%, against +312.9% for the S&P 500 (SPY). It sits 28.7% above its 200-day average of $135.15, the usual sign of a long-term uptrend. Its 30-day volatility is 29.2% annualized, which we rate medium risk. It has a trailing P/E of 34.3 and a dividend yield of 0.57%.
Cite: Portfolio Terminal, "Agilent Technologies (A) stock analysis", 2026-10-22. https://portfolio-terminal.com/analyse/a
Where it trades today
trading 93% of the way up its 52-week range
How the price has moved
How far it is from its record
Agilent Technologies (A) is 3.2% below its all-time high of $179.57, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +294.8%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- A trades at 34.3x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 29.2%, above the sector norm of 22.0%, so position sizing matters more than usual.
- A is in a bullish short-term regime and only 2.9% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- A is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in A.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for A come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for A. Last refresh: Oct 22, 2026, 8:26 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Agilent Technologies does
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance,…
Employees
18,200
Industry
Diagnostics & Research
Headquarters
Santa Clara, United States
What analysts expect
A carries a buy consensus from 19 analysts, with an average price target of $180.58 versus $173.89 today (+3.8%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
A generated $7.37B in trailing revenue (8.1% year over year), with a 19.5% net margin, and $1.06B of free cash flow, against $2.39B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $6.95B | $3.64B | $1.48B | $1.30B | $4.59 | $1.15B |
| 2024 | $6.51B | $3.54B | $1.49B | $1.29B | $4.44 | $1.37B |
| 2023 | $6.83B | $3.46B | $1.35B | $1.24B | $4.22 | $1.47B |
| 2022 | $6.85B | $3.72B | $1.62B | $1.25B | $4.19 | $1.02B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
A is in 16 of the 54 ETFs we track. It weighs most in XLV: 0.76% of the fund, holding #30 of 62.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
A beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, 2.9% under its 1-year high with no resistance above.
uptrend- Price is 8.0% above its 50-day average and 28.7% above its 200-day.
- The 50-day crossed above the 200-day on 2026-07-30 (a “golden cross”).
- RSI at 59 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $163.54 (-6.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is A a good investment in 2026?
Agilent Technologies trades at a P/E ratio of 34.3, with medium volatility (29.2% annualized). Recent momentum is positive.
What is the risk level of A?
Based on 30-day volatility of 29.2%, A has MEDIUM risk. Beta of 1.21 indicates higher sensitivity to market movements than average.
Does A pay dividends?
Yes, Agilent Technologies has a dividend yield of 0.57%.
How far is A from its all-time high?
Agilent Technologies is 3.2% below its all-time high of $179.57, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +294.8%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold A?
16 of the 54 popular ETFs we track hold Agilent Technologies. The largest weights: XLV (0.76%), VO (0.48%), RSP (0.24%), VIG (0.22%) and VTV (0.18%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is A?
0.07%, as of September 30, 2026: A is holding #224 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.74 in Agilent Technologies.
What is the analyst price target for A?
The average analyst price target for Agilent Technologies (A) is $180.58 based on 19 analyst estimates, about 3.8% above the current price of $173.89. The published range runs from $155.00 to $196.00.
How much revenue does A generate?
Agilent Technologies reported $7.37B in trailing twelve-month revenue. Revenue growth is running at 8.1% year over year. Net margin sits at 19.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare A with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.